<?xml version="1.0" encoding="UTF-8"?>
<p id="p0115">The intranasal topical application of 0.08% solution of iodine for the treatment of recalcitrant chronic rhinosinusitis has been described by the St. Paul's Sinus Centre team in Vancouver [
 <xref rid="bb0085" ref-type="bibr">17</xref>,
 <xref rid="bb0090" ref-type="bibr">18</xref>]. This application did not cause any significant effect on thyroid function, mucociliary clearance or olfaction. PVP-I use in the nasal cavity to reduce infection or spread is rational for COVID-19 after two recent trials have demonstrated higher viral load there when compared with the oral cavity [
 <xref rid="bb0025" ref-type="bibr">5</xref>,
 <xref rid="bb0030" ref-type="bibr">6</xref>,
 <xref rid="bb0040" ref-type="bibr">8</xref>].
</p>
